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Increased levels of systemic 
LPS-positive bacterial 
extracellular vesicles in patients 
with intestinal 
barrier dysfunction
We read with interest recent papers 
reporting on the impact of gut microbiota 
on several aspects of health and disease due 
to altered intestinal permeability resulting 
in systemic immune activation by patho-
gen-associated molecular patterns (PAMP), 
a process termed microbial translocation.1–4 
Common to these studies is the analysis of 
systemic lipopolysaccharide (LPS), the major 
outer membrane PAMP of Gram-negative 
bacteria, to quantitatively assess microbial 
translocation. While systemic LPS is typi-
cally regarded as a soluble product, either 
or not neutralised by lipoproteins and endo-
toxin core antibodies, LPS is also released 
as a membrane-associated PAMP through 
extracellular vesicles (EV).5–7 Bacterial EV 
are nanometre-sized membrane particles 
transporting nucleic acids, metabolites, 
proteins and endotoxins.8 As such, bacterial 
EV that enter the systemic circulation may 
deliver and elicit a variety of immunological 
and metabolic responses in different organs 
including the brain.9 To date, the systemic 
presence and activity of bacterial EV in 
patients with intestinal barrier dysfunction 
have not been investigated.
Here, we fractionated plasma of 49 
subjects to distinguish bacterial EV-associ-
ated LPS from other LPS products (online 
supplementary file 1). Online supplemen-
tary table 1 summarises individual patient 
characteristics; 25 donors asymptomatic of 
intestinal barrier dysfunction (12 healthy 
volunteers and 13 patients with cancer 
during chemotherapy without GI side 
effects suggestive for intestinal mucositis) 
and 24 patients with clinically well-defined 
intestinal barrier dysfunction (13 patients 
with IBD, 5 patients with cancer with radi-
ation or chemotherapy-induced intestinal 
mucositis and 6 treatment-naive patients 
with HIV). We quantitatively measured 
bacterial EV-associated LPS and other LPS 
products by performing limulus amoebocyte 
lysate (LAL) and Toll-like receptor 4 (TLR4) 
reporter assays and qualitatively confirmed 
the results by immunoelectron micros-
copy (online supplementary figure 1). We 
combined size exclusion chromatography 
and density gradient (DG) centrifugation to 
fractionate plasma LPS in two dimensions to 
separate bacterial EV-associated LPS from 
other LPS products (online supplementary 
figures 2 and 3).
LAL analysis of DG fraction 5 (1.141–
1.186 g/mL), corresponding to the density 
of bacterial EV (online supplementary 
figure 2), demonstrated significantly 
increased LPS activity in patients diagnosed 
with HIV, IBD and therapy-induced intes-
tinal mucositis compared with respective 
controls (figure 1A–C). LAL analysis of the 
lower density fractions (1.041–1.068 g/mL), 
containing other LPS products, revealed no 
significant difference (online supplemen-
tary figure 4). In accordance, we detected 
elevated amounts of microbial pattern 
recognition receptor ligands by determining 
TLR4 agonistic activity in DG fraction 5 of 
patients with intestinal barrier dysfunction 
(figure 1D). Immunoelectron microscopy 
confirmed bacterial EV-associated LPS in 
DG fraction 5 (figure 1E).
Zonulin, a biomarker of barrier integ-
rity, initiates phosphorylation of zonula 
occludens proteins and leads to tight 
junction disassembly and increased intes-
tinal permeability.10 The level of bacterial 
EV-associated LPS significantly correlated 
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Figure 1 Quantitative and qualitative assessment of lipopolysaccharide (LPS)-positive bacterial extracellular vesicles (EV) isolated from plasma of 
patients with intestinal barrier dysfunction. (A–C) Box and whisker plots of LPS activity levels, (D) z-score transformation of Toll-like receptor 4 (TLR4) 
agonistic activity levels, and (E) immunoelectron microscopy analysis (scale bar=200 nm) of systemic bacterial EV in patients diagnosed with HIV, IBD 
and cancer therapy-induced intestinal mucositis compared with respective controls (each block represents one individual). (F) Correlation analysis 
between plasma zonulin and bacterial EV-associated LPS activity levels (Spearman’s r=0.4241, p=2.45×10−2). EU, endotoxin unit.
 on 6 D
ecem
ber 2018 by guest. P
rotected by copyright.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2018-317726 on 5 D
ecem
ber 2018. D
ow
nloaded from
 
2 Gut Month 2018 Vol 0 No 0
PostScript
with plasma zonulin levels, suggesting an 
association with intestinal barrier integrity 
(figure 1F). Indeed, compromising tight 
junction integrity in an in vitro colitis 
model induced paracellular translocation 
of bacterial EV (online supplementary 
figure 5). We calculated that the human 
gut harbours approximately 1014 bacte-
rial EV which may serve as a substan-
tial source of systemic PAMP, evidenced 
by proteomic analysis of faeces-derived 
bacterial EV (online supplementary figure 
6D,E). Additionally, bacterial EV strongly 
stimulated secretion of proinflammatory 
cytokines (such as interleukin (IL)-6, IL-8, 
MCP-1 and MIP-1α) by peripheral blood 
mononuclear cells, whereas the secretion 
of receptor antagonists (such as IL-1RA) 
was not stimulated, indicating potent 
systemic aspects (online supplementary 
figure 6F).
In conclusion, LPS-positive bacterial EV 
are present in plasma, are able to induce 
immune activation and correlate with 
impaired barrier integrity in patients diag-
nosed with IBD, HIV and cancer thera-
py-induced intestinal mucositis (figure 2). 
Further studies are needed to understand 
systemic functions of circulating bacterial 
EV, to study their biomarker potential and 
to identify and correlate their taxonomy 
to the metabolic activity status of gut 
microbiota.
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Figure 2 Intestinal barrier dysfunction opens the door for bacterial EV-associated LPS and other LPS products to enter the systemic circulation and 
induce immune activation. EV, extracellular vesicles; LPS, lipopolysaccharide. 
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